TABLE 2

Clearance obtained for 10 drugs in the presence and absence of BSA using combined P450 and UGT cofactors and scaled to in vivo

Compound	CL_{int, u} (P450 + UGT)			-Fold Difference: Cl_{int, u} + BSA/CL_{int, u} - BSA	fu_mic			Scaled CL_{int, u}^a
Compound		-BSA	+BSA	-Fold Difference: Cl_{int, u} + BSA/CL_{int, u} - BSA		-BSA	+BSA	-BSA	+BSA
	μl/min/mg						ml/min/kg
Buprenorphine	688	577	0.84	0.10	0.17	588.9	494
Carvedilol	356	246	0.69	0.10	0.04	305	210
Codeine	3.4	16.9	5.0	0.96	0.99	2.9	14.5
Diclofenac	369	2143	5.8	0.87	0.008	316	1834
Gemfibrozil	97.3	1274	13.0	0.77	0.01	83.3	1090
Ketoprofen	26.0	115	4.4	0.92	0.11	22.2	98.5
Midazolam	159	241	1.5	0.54	0.04	137	207
Naloxone	14.4	35.1	2.4	0.87	0.99	12.3	30.1
Raloxifene	544	1812	3.3	0.08	0.009	465	1551
Zidovudine	2.8	13.2	4.7	0.60	0.49	2.4	11.3

↵ a CL_{int, u} was scaled using a human microsomal scaling factor of 40 mg protein/g liver (Ito and Houston, 2005; Barter et al., 2007) and an average liver weight of 21.4 g liver/kg.